Pfizer Opposes Proton Pump Inhibitor MDL, Says 60-Plus Defendants Could be Involved
December 5, 2016
- AstraZeneca Brief
- Pfizer Brief
WASHINGTON, D.C. — Pfizer Inc. is the latest defendant in the Proton Pump Inhibitor (PPI) personal injury litigation to oppose a recent motion by plaintiffs to create a multidistrict litigation docket in Louisiana for all similar cases filed in federal court.
In a Nov. 22 brief, the drug maker contends that the various alleged injuries, multitude of prescription and over-the-counter PPI drugs on the market — along with the potential involvement in the litigation of more than 60 possible defendants — make the case unfit for centralization.
Pfizer argues that, as a manufacturer of an OTC product that is named …
- Ice Miller
- McCarter & English
- Skadden, Arps, Slate, Meagher & Flom